HRD phenotypes in breast, ovarian, pancreatic, and prostate cancers have been associated with germline and somatic mutations as well as suppression of epigenetic modifications in BRCA1 and BRCA2. This evidence concerns the gene BRCA2 and prostate carcinoma.